Keyword Search


     

Contact Us


EMAIL US

     

Event ID : ADDF
Alzheimers Drug Discovery Foundation
4th DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE
Houston, TX
February 1-2, 2010


ABOUT THE MEETING

The purpose of the conference is to advance drug discovery for neurodegenerative diseases by educating scientists on the process of translating basic research into novel therapies.
Speakers and chairs present lectures and case studies on Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, ALS, MS, and other orphan neurological diseases.

COURSE OBJECTIVES
  • Discuss the principles of drug discovery for neurodegenerative disease.

  • Exchange ideas, knowledge and resources about drug discovery for neurodegenerative disease.

  • Stimulate pre-clinical research in the discovery and testing of novel compounds aimed at the prevention and treatment of neurodegenerative disease.

  • Build public-private partnerships that will accelerate drug discovery for neurodegenerative disease.

TARGET AUDIENCE

  • Academic and industry scientists engaged in drug discovery research for neurodegenerative diseases or CNS

  • Business development and licensing professionals

  • Alliance management professionals

  • Venture capitalists and other investors.



For more information visit: http://www.worldeventsforum.com/addf/2010/index.html


Table of Contents
4th DRUG DISCOVERY FOR NEURODEGENERATION
I. Basics of Medicinal Chemistry
II. In-vitro Testing: Early Phases of Drug Discovery
III. Pre-Clinical Proof-of-Concept & Development
IV. Issues in Technology Transfer: Interactions and Intellectual Property
VI. Resources and Services For Advancing Drug Discovery


4th DRUG DISCOVERY FOR NEURODEGENERATION

Objectives :

The purpose of the conference is to advance drug discovery for neurodegenerative diseases by educating scientists on the process of translating basic research into novel therapies. 

Speakers and chairs present lectures and case studies on Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, ALS, MS, and other orphan neurological diseases.



______________________

Overview of Drug Discovery for Neurodegenerative Disease

Speaker(s) : Howard Fillit, MD



______________________

Stem Cells to Accelerate Drug Discovery for Neurodegenerative Disease

Speaker(s) : Lee Rubin, PhD





I. Basics of Medicinal Chemistry

Objectives :
The goal of this session is to review fundamentals of medicinal chemistry relevant to drug discovery for CNS disorders. Although the focus is on small molecule drugs, due to the extensive state of knowledge, general themes relevant to peptide and protein therapeutics will also be discussed. The attendee should leave the session with a practical, working familiarity of contemporary approaches and key issues that should be considered by interdisciplinary teams as they take hits to lead compounds to candidate small molecule therapeutics.

______________________

Overview: Medicinal Chemistry Rules of Thumb, Myths and Realities in CNS Drug Discovery

Speaker(s) : D. Martin Watterson, PhD



______________________

Designing Small Molecules with Increased Potential for CNS Penetration

Speaker(s) : Laura Chico, MS, PhD



______________________

Synthetic Chemistry Essentials for Biologists

Speaker(s) : Heather Behanna, PhD





II. In-vitro Testing: Early Phases of Drug Discovery

Objectives :

A key component of the development of new therapeutic agents is the identification of molecules that can serve as initial lead structures on which drug discovery programs can be built.  High-throughput screening of large collections of drug-like molecules for modulatory activity in disease-relevant assays is an important means to discovering these lead molecules.  This session will first address strategies for selecting your target, then the development of assays that are suitable for high-throughput screening and for secondary assays to validate the primary screening results.  Most drug development efforts fail due to toxicity and ADME (absorption, distribution, metabolism and excretion) properties. This session will end with a presentation on technology used for in vitro toxicity and ADME testing.



______________________

Developing Relevant High-Throughput Assays for the Identification of Potential Drug Candidates

Speaker(s) : Marcie Glicksman, PhD



______________________

Role of In Vitro Models in Drug Discovery for Neurodegenerative Disease

Speaker(s) : Lisa Minor, PhD



______________________

In Vitro Toxicity Testing: What, Why & How

Speaker(s) : Karen L. Steinmetz, PhD, DABT





III. Pre-Clinical Proof-of-Concept & Development

Objectives :

Preclinical development, the phase of drug development between discovery and clinical trial, is often referred to as the “Valley of Death”.  Several factors contribute to this barren landscape.  Many promising leads fail due to problems of formulation, delivery, bioavailability, scalable manufacturing, or safety.   Investigators seeking to navigate past these hazards also encounter challenges in funding, resources, and expertise.  This session offers an overview of the steps involved in optimization of a lead compound and in vivo efficacy and safety studies that determine dosing strategies.  Presentations will include examples of go/no-go stage decision points, funding resources, and outsourcing options to complete the journey of discovery to an Investigational New Drug (IND) application for clinical trial.



______________________

Requirements for a Lead Compound to Become a Clinical Candidate

Speaker(s) : Nancy Wehner, PhD



______________________

Behavioral Testing in Neurodegenerative Disease

Speaker(s) : Taleen Hanania, PhD

______________________

Regulatory Requirements & Strategy

Speaker(s) : Joy Cavagnaro, PhD



______________________

The Basics of Pre-Clinical Development

Speaker(s) : Edward Spack, PhD, MS





IV. Issues in Technology Transfer: Interactions and Intellectual Property

Objectives :
This session will focus on the interactions among academic researchers, their technology transfer office and industry partners.  An introduction will discuss the various roles and responsibilities of all of the parties involved and hope to begin to demystify academic – industry relations.  The basics of patents will be presented with an emphasis on what they can and cannot successfully cover, as well as what a researcher needs to do to maximize the chances of a positive outcome.  A variety of agreements used in academic – industry relationships will also be discussed, with an emphasis on the importance of creating a good relationship amongst all parties.  The session will continue with an honest appraisal of the good, the bad and the ugly of new company formation in the biotech industry, and finally close with an industry perspective on dealing with academic institutions.

______________________

Working Effectively with Your TTO: Roles and Responsibilities

Speaker(s) : Kathleen Denis, PhD



______________________

Intellectual Property 101: A Primer For Investigators

Speaker(s) : Colin G. Sandercock



______________________

Creating Relationships with Industry: Consulting, Research, MTA

Speaker(s) : Louis Berneman, EdD, CLP



______________________

Should You Start a Biotechnology Company?

Speaker(s) : John S. Swartley, PhD



______________________

What Companies Look for in a Licensing Partner

Speaker(s) : Susan P. Rohrer, PhD





VI. Resources and Services For Advancing Drug Discovery

Objectives :
This session will focus on descriptions of the resources available through a variety of mechanisms within academia, the National Institutes of Health (NIH), foundations and commercial vendors.  Speakers will focus on resources for assay development, target identification, drug discovery, drug development, pre-clinical toxicology evaluation and other components needed for the translation of pre-clinical drug candidates into potential therapies tested in clinical trials. In particular, it will include specific descriptions of programs available to academic investigators through individual NIH Institutes, including the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS), as well as trans-NIH programs including the NIH Roadmap for Medical Research and the NIH Blueprint for Neuroscience Research.

______________________

How to Outsource Early Drug Discovery

Speaker(s) : Mark Creswell, PhD



______________________

Resources at the National Institute of Health

Speaker(s) : William Matthew, PhD



______________________

Types of Academic Drug Discovery Programs

Speaker(s) : Euan Ramsey, PhD



______________________

Foundation Resources

Speaker(s) : Howard Fillit, MD , Leticia M. Toledo-Sherman, PhD , Tim Coetzee, PhD, MS

  • Venture Philanthropy—Howard Fillit, MD, ADDF; Other Philanthropic Approaches — Tim Coetzee, PhD, MS Fast Forward; Funding and other challenges for rare diseases — Leticia M. Toledo-Sherman, PhD, CHDI Foundation




Contact Us : customersupport@dcproviders.com
Digital Conference Providers, Inc. - 100 S. Cass Ave. Ste 200 - Westmont, IL 60559
Phone (630) 963-8311 - Fax (630) 963-8312